Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorEstévez-Vázquez, Olga
dc.contributor.authorBenedé-Ubieto, Raquel
dc.contributor.authorGuo, Feifei
dc.contributor.authorGómez-Santos, Beatriz
dc.contributor.authorAspichueta, Patricia
dc.contributor.authorReissing, Johanna
dc.contributor.authorPericàs Pulido, Juan Manuel
dc.contributor.authorCiudin Mihai, Andreea
dc.date.accessioned2022-03-11T12:00:39Z
dc.date.available2022-03-11T12:00:39Z
dc.date.issued2021-10
dc.identifier.citationEstévez-Vázquez O, Benedé-Ubieto R, Guo F, Gómez-Santos B, Aspichueta P, Reissing J, et al. Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). Biomedicines. 2021 Oct;9(10):1289.
dc.identifier.issn2227-9059
dc.identifier.urihttps://hdl.handle.net/11351/7139
dc.descriptionFibrosis; Obesity; Palmitic acid (PA)
dc.description.abstractObjectives: Lately, many countries have restricted or even banned transfat, and palm oil has become a preferred replacement for food manufacturers. Whether palm oil is potentially an unhealthy food mainly due to its high content of saturated Palmitic Acid (PA) is a matter of debate. The aim of this study was to test whether qualitative aspects of diet such as levels of PA and the fat source are risk factors for Metabolic Syndrome (MS) and Metabolic Associated Fatty Liver Disease (MAFLD). Methods: C57BL/6 male mice were fed for 14 weeks with three types of Western diet (WD): 1. LP-WD—low concentration of PA (main fat source—corn and soybean oils); 2. HP-WD—high concentration of PA (main fat source—palm oil); 3. HP-Trans-WD—high concentration of PA (mainly transfat). Results: All types of WD caused weight gain, adipocyte enlargement, hepatomegaly, lipid metabolism alterations, and steatohepatitis. Feeding with HP diets led to more prominent obesity, hypercholesterolemia, stronger hepatic injury, and fibrosis. Only the feeding with HP-Trans-WD resulted in glucose intolerance and elevation of serum transaminases. Brief withdrawal of WDs reversed MS and signs of MAFLD. However, mild hepatic inflammation was still detectable in HP groups. Conclusions: HP and HP-Trans-WD play a crucial role in the genesis of MS and MAFLD.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesBiomedicines;9(10)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsteatosi hepàtica
dc.subjectÀcids grassos saturats - Metabolisme
dc.subjectRatolins
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.mesh/metabolism
dc.subject.meshTrans Fatty Acids
dc.subject.mesh/adverse effects
dc.titleFat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/biomedicines9101289
dc.subject.decsesteatosis hepática alcohólica
dc.subject.decs/metabolismo
dc.subject.decsácidos grasos trans
dc.subject.decs/efectos adversos
dc.relation.publishversionhttps://doi.org/10.3390/biomedicines9101289
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Estévez-Vázquez O, Benedé-Ubieto R] Department of Physiology, Genetics and Microbiology, Faculty of Biology, Complutense University of Madrid, 28040 Madrid, Spain. Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain. [Guo F] Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain. [Gómez-Santos B] Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, 48940 Leioa, Spain. [Aspichueta P] Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, 48940 Leioa, Spain. Biocruces Health Research Institute, 48903 Barakaldo, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28220 Madrid, Spain. [Reissing J] Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. [Ciudin A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Pericàs JM] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28220 Madrid, Spain. Unitat del Fetge, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid34680405
dc.identifier.wos000712389800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record